The Clinical Research Report

on the Fandetox made with Bionutrigen's JBB20S and Exported to Russia.

February 10, 2022

Fandetox clinical study December 12, 2021 Reported by:

Ministry of Health of the Russian Federation

Federal State Budgetary Higher Education Facility

Siberian State Medical University

(FGBOU VO SIBGMU MINISTRY OF HEALTH OF RUSSIA)

CLINICAL STUDY REPORT

RANDOMIZED OPEN COMPARATIVE STUDY FOR EVALUATION OF EFFECTIVENESS OF BIOLOGICALLY ACTIVE SUPPLEMENT FANDETOX AS SOURCE OF ORGANIC COMPOUNDS IN LIVER DISORDERS

Dr. Song Hae Bok

CEO, Bionutrigen Co., Ltd.

◑ Tel : +82-42-861-0637~8

◑ Fax : +82-42-861-0639

◑ e-mail : bionutrigen@hanmail.net

◑ website : www.bionutrigen.com

Results and Conclusions : 

Currently, fatty hepatosis is one of the most common liver diseases which can lead to deterioration in the quality of life. Non-alcoholic fatty liver disease is the disease that, like an invisible person, often goes unnoticed. Of those nonspecific symptoms that are worth paying attention to, the following are distinguished: weakness, fatigue, and sleep disturbance.

Based on the results of the clinical study performed, the following conclusions can be drawn:

1. The inclusion of the biologically active supplement FanDetox in the complex therapy of fatty hepatosis and obesity contributes to the improvement of the subjective well-being of patients.

2. When taking the dietary supplement FanDetox, there was a significant decrease in manifestations of fatty hepatosis and decrease in the liver size according to ultrasound control compared with the comparison group.

3. There was the tendency to normalize fat metabolism, a decrease in dyslipidaemia in the comparison group, and changes in the lipid profile of patients.

4. In control tests of blood biochemistry, a decrease in the cytolysis syndrome and the bilirubin levels were noted.

5. The tolerance of the dietary supplement FanDetox was good, and no adverse events associated with taking the food supplement were registered.

6. The biologically active supplement FanDetox is recommended as the part of the complex therapy for treatment of patients with obesity, dyslipidemia, hepatitis of various origin (drug-induced, metabolic).

Clinical investigators have been working with the biologically active supplement FanDetox for almost 6 months observing the positive effect and including the product in routine practice of the department of HTC of the Siberian State Medical University. Currently, against the COVID-19 pandemic, patients with post-covid syndrome, after infection, with complications in the form of drug-induced hepatitis, colitis, and myocarditis are observed in the clinic. This group of patients was not included in the current study, but when prescribing the food supplement FanDetox to patients with drug-induced hepatitis with the COVID-19 therapy, it was successful, and may become the goal of the study of this food supplement in the future.